GlassScriptPhysician profile
Gary Allen Levinson
NPI 1841228228
$263.44
in general payments reported to CMS, 2019-2025
9 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $70.96 · 2020: $112 · 2022: $80.80.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $67.00 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $55.58 | 2019-2020 | |
| Abbvie INC. | $52.70 | 2020-2022 | |
| Daiichi Sankyo INC. | $24.29 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.78 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $13.63 | 2020 | |
| Lundbeck LLC | $12.73 | 2020 | |
| Mdd US Operations, LLC | $11.65 | 2019 | |
| Amgen INC. | $11.08 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Levinson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.